Rare retina research ramps up

Inherited retinal diseases are genetic disorders that slowly damage the light-sensing cells in the eye, often over years or decades. A February 27 review in *Ophthalmology Times* said that pipeline is moving from theory to active trials in retinitis pigmentosa and Stargardt disease. (ophthalmologytimes.com) Retinitis pigmentosa is a group of disorders that usually narrows side vision first and can end in severe blindness. Stargardt disease more often hits central vision, often starting in childhood or young adulthood, because toxic byproducts build up in the retina. (ophthalmologytimes.com) (fightingblindness.org) The treatment problem is basic but hard: many of these diseases come from different gene errors, and the retina is delicate tissue at the back of the eye. That is why developers are testing several delivery routes, including subretinal surgery, intravitreal injection into the eye, and suprachoroidal delivery around the eye wall. (ophthalmologytimes.com) On the retinitis pigmentosa side, the review highlighted two different approaches already showing human data. HORA-PDE6b reported visual-function benefit at 24 months in patients with bi-allelic PDE6B mutations, while MCO-010 showed sustained three-line vision gains through 152 weeks in advanced disease. (ophthalmologytimes.com) (coavetx.com) (nanostherapeutics.com) Another retinitis pigmentosa program moved on the regulatory front this month. Ray Therapeutics said on April 1 that the Food and Drug Administration granted regenerative medicine advanced therapy designation to RTx-015, an optogenetic gene therapy for retinitis pigmentosa. (raytherapeutics.com) (ophthalmologytimes.com) Stargardt programs are trying to solve a different engineering problem: the ABCA4 gene is too large for standard single-vector delivery. The review pointed to dual-adeno-associated virus approaches such as VG801 and AAVB-039, plus SB-007, described as the first Food and Drug Administration-authorized protein-splicing trial in this setting. (ophthalmologytimes.com) (fightingblindness.org) That Stargardt field kept moving after the review. Foundation Fighting Blindness said on April 14 that SpliceBio’s SB-007 had entered dose expansion in phase 1/2, and VeonGen said VG801 had shown no dose-limiting or serious adverse events to date, with nine patients through six-month follow-up and some through 12 months. (fightingblindness.org) (veongen.com) Drug programs that are not classic gene therapy are also posting data. Foundation Fighting Blindness said Alkeus’s ALK-001 slowed Stargardt lesion growth by about 30% in phase 2 studies, and Belite Bio reported Tinlarebant slowed atrophic lesion growth by 36% versus placebo in the phase 3 DRAGON trial. (fightingblindness.org) Diagnosis is becoming part of the story, not just treatment. The *Ophthalmology Times* review cited deep learning on true-color fundus photos that differentiated retinitis pigmentosa and Stargardt disease with 97.9% overall accuracy, and a 2025 *Scientific Reports* paper described a multi-input model built to detect those two inherited retinal diseases from imaging. (ophthalmologytimes.com) (nature.com) A separate 2025 *Nature Medicine* paper on Eye2Gene pushed that idea further by using multimodal eye images to improve screening and variant prioritization in inherited retinal disease. In plain terms, the software looks for recurring visual patterns that can help doctors decide which patients need genetic testing fastest. (nature.com) The practical effect is that retina clinics are under more pressure to catch these patients early, document the phenotype with imaging, and send them for genetic workups before vision is lost. As more mutation-specific and mutation-agnostic programs move through trials, the bottleneck is shifting from “nothing to offer” to “finding the right patient in time.” (retinalphysician.com) (ophthalmologytimes.com)